Category: Research
FSR Well-Represented at SCOPE 2017
FSR’s Ginger Spitzer will be presenting at the 8th annual Summit for Clinical Ops Executives, or SCOPE in Miami, FL later this month. SCOPE is a 3-day summit of conferences, workshops and symposiums, all dedicated to productive and in-depth conversations the...
Baltimore Clinical Trial for Neurosarcoidosis Patients
For all neurosarcoidosis patients, a clinical trial in the Baltimore area entitled, “Clinical Biomarkers of Disease Activity and Treatment Response in Patients with CNS Sarcoidosis Treated with H.P. Acthar Gel”, is now open for recruitment specifically to patients in...
Hospitals start comparing health outcomes internationally
A new collaboration between six hospitals around the world is allowing doctors to exchange data and compare case outcomes, in order to establish best practices when it comes to treating sarcoidosis. The press release announcement is below: Nieuwegein / Utrecht, 13...
San Francisco Research Studies Looking for Participants
UCSF Sarcoidosis Studies are Recruiting! San Francisco based studies are looking for people diagnosed with sarcoidosis in or near the bay area to join us in learning more about this disease. All studies are currently observational (no interventions), looking closely...
Why Clinical Trials Fail: FSR’s New Initiative to Bridge Gap between Industry Leaders, Researchers, and Patients
Guest post written by Sue Bhalla As the latest industry statistics show, an estimated 90% of drugs that reach the testing phase of clinical trials never end up marking the finish line and attaining FDA approval. This leaves potentially useful drug therapies far from...Accelerate Research for Sarcoidosis at K.I.S.S. 5K in Chicago!
Kick In to Stop Sarcoidosis at the Foundation for Sarcoidosis Research’s 3rd Annual 5K in Chicago, IL! Saturday, April 30, 2016 at 10:30am Grove 3, Lincoln Park, Chicago, IL You will help us create a movement by raising awareness for sarcoidosis and doing your...
SAKURA Phase III Study
The SAKURA study is a Phase III, multinational, double-masked trial investigating the safety and efficacy of DE-109 for the treatment of non-infectious uveitis of the posterior segment. DE-109 is a proprietary formulation of sirolimus that is an anti-inflammatory...